Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Gadhiya et al. Vitamin C for COVID-19 LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 281 patients in the USA Study underpowered to detect differences Gadhiya et al., BMJ Open, doi:10.1136/bmjopen-2020-042549 Favors vitamin C Favors control
Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state
Gadhiya et al., BMJ Open, doi:10.1136/bmjopen-2020-042549
Gadhiya et al., Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network,.., BMJ Open, doi:10.1136/bmjopen-2020-042549
Apr 2021   Source   PDF  
  All Studies   Meta
Retrospective 283 patients in the USA showing higher mortality with all treatments (not statistically significant). Confounding by indication is likely. In the supplementary appendix, authors note that the treatments were usually given for patients that required oxygen therapy. Oxygen therapy and ICU admission (possibly, the paper includes ICU admission for model 2 in some places but not others) were the only variables indicating severity used in adjustments. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death, 0.7% higher, RR 1.01, p = 0.98, treatment 19 of 55 (34.5%), control 36 of 226 (15.9%), adjusted per study, odds ratio converted to relative risk, multivariate logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gadhiya et al., 8 Apr 2021, retrospective, USA, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Open access Original research Kinjal P Gadhiya,1 Panupong Hansrivijit ‍ ‍,1 Mounika Gangireddy,1 John D Goldman2 To cite: Gadhiya KP, Hansrivijit P, Gangireddy M, et al. Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-­network, retrospective cohort study from Pennsylvania state. BMJ Open 2021;11:e042549. doi:10.1136/ bmjopen-2020-042549 ►► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://​dx.​doi.o​ rg/​10.​1136/​ bmjopen-​2020-​042549). KPG, PH and MG contributed equally. Received 08 July 2020 Revised 07 October 2020 Accepted 18 March 2021 © Author(s) (or their employer(s)) 2021. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. 1 Department of Internal Medicine, UPMC Pinnacle, Harrisburg, Pennsylvania, USA 2 Department of Infectious Diseases, UPMC Pinnacle, Harrisburg, Pennsylvania, USA Correspondence to Dr Panupong Hansrivijit; h​ ansrivijitp@​upmc.e​ du ABSTRACT Objective COVID-19 is a respiratory disease caused by SARS-­CoV-2 with the highest burden in the USA. Data on clinical characteristics of patients with COVID-19 in US population are limited. Thus, we aim to determine the clinical characteristics and risk factors for in-­hospital mortality from COVID-19. Design Retrospective observational study. Setting Single-­network hospitals in Pennsylvania state. Participants Patients with confirmed SARS-­CoV-2 infection who were hospitalised from 1 March to 31 May 2020. Primary and secondary outcome measures Primary outcome was in-­hospital mortality. Secondary outcomes were complications, such as acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS). Results Of 283 patients, 19.4% were non-­survivors. The mean age of all patients was 64.1±15.9 years. 56.2% were male and 50.2% were white. Several factors were identified from our adjusted multivariate analyses to be associated with in-­hospital mortality: increasing age (per 1-­year increment; OR 1.07 (1.045 to 1.105)), hypoxia (oxygen saturation <95%; OR 4.630 (1.934 to 1.111)), opacity/infiltrate on imaging (OR 3.077 (1.276 to 7.407)), leucocytosis (white blood cell >10 109/µL; OR 2.732 (1.412 to 5.263)), ferritin >336 ng/mL (OR 4.016 (1.195 to 13.514)), lactate dehydrogenase >200 U/L (OR 7.752 (1.639 to 37.037)), procalcitonin >0.25 ng/ mL (OR 2.404 (1.011 to 5.714)), troponin I >0.03 ng/ mL (OR 2.242 (1.080 to 4.673)), need for advanced oxygen support other than simple nasal cannula (OR 4.608–13.889 (2.053 to 31.250)), intensive care unit admission/transfer (OR 13.699 (6.135 to 30.303)), renal replacement therapy (OR 21.277 (5.025 to 90.909)), need for vasopressor (OR 22.222 (9.434 to 52.632)), ARDS (OR 23.810 (10.204 to 55.556)), respiratory acidosis (OR 7.042 (2.915 to 16.949)), and AKI (OR 3.571 (1.715 to 7.407)). When critically ill patients were analysed independently, increasing Sequential Organ Failure Assessment score (OR 1.544 (1.168 to 2.039)), AKI (OR 2.128 (1.111 to 6.667)) and ARDS (OR 6.410 (2.237 to 18.182)) were predictive of in-­hospital mortality. Strengths and limitations of this study ►► Individual patient’s chart was reviewed. ►► Multivariate analysis (binary logistic regression model) was used to report the results. ►► Retrospective, observational design. ►► Limited sample size. ►► Only hospitalised patients were..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop